LAMEA Narcolepsy Therapeutics Market Size, Share & Industry Trends Analysis Report By Type, By Product (Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants), By Country and Growth Forecast, 2022 - 2028

The Latin America, Middle East and Africa Narcolepsy Therapeutics Market is expected to witness market growth of 16.5% CAGR during the forecast period (2022-2028).

The neurotransmitter hypocretins control the sleep-wake cycle as well as other metabolic processes. Researchers have found that people with cataplexy and narcolepsy have lost hypocretin-producing cells in the brain's hypothalamus. Although it is an auto-immune illness, the reason why hypocretin cells are destroyed is not yet understood.  The third most frequent sleep disorder identified narcolepsy affects a significant portion of the population.

Although narcolepsy cannot be cured, it can be managed with medications like methylphenidate, dextroamphetamine, and others to lessen the frequency of sleep attacks. In narcolepsy, the common tetrad of hypnagogic hallucinations, sleep paralysis, and cataplexy (a sudden loss of muscular tone on both sides) occur in combination with severe daytime fatigue and uncontrollable sleep episodes. Cataplexy, which is the term for bouts of rapid loss of muscle strength that affect about 70% of people, can be triggered by intense emotions.

The medical students and healthcare providers have reportedly been found to frequently have poor sleep quality. Increased rates of burnout and depression have been linked to sleep disruption. Performance and functionality have suffered as a result of this. In the United Arab Emirates, there is little research on this subject (UAE). In this study, medical and dental students in Dubai, United Arab Emirates, will have their sleep habits and mental states examined.

The Brazil market dominated the LAMEA Narcolepsy Therapeutics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $118.4 million by 2028.The Argentina market is experiencing a CAGR of 17.1% during (2022 - 2028). Additionally, The UAE market is expected to display a CAGR of 16.2% during (2022 - 2028).

Based on Type, the market is segmented into Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy. Based on Product, the market is segmented into Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Jazz Pharmaceuticals plc, Shionogi & Co., Ltd., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc. (Arena Pharmaceuticals, Inc.), Bioprojet, Takeda Pharmaceutical Company Limited, Ligand Pharmaceuticals, Inc., and Graymark Healthcare, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Type

• Narcolepsy with Cataplexy
• Narcolepsy Without Cataplexy
• Secondary Narcolepsy

By Product

• Sodium Oxybate
• Selective Serotonin Reuptake Inhibitor
• Central Nervous System Stimulants
• Tricyclic Antidepressants
• Others

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Jazz Pharmaceuticals plc
• Shionogi & Co., Ltd.
• Teva Pharmaceuticals Industries Ltd.
• Pfizer, Inc. (Arena Pharmaceuticals, Inc.)
• Bioprojet
• Takeda Pharmaceutical Company Limited
• Ligand Pharmaceuticals, Inc.
• Graymark Healthcare, Inc.

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free